An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas

Inclusion Criteria: * Type 1 diabetes for at least 1 year * insulin pump for ≥ 6 months * Prescription medication regimen stable for \> 1 month * Subject comprehends written English * Female patients who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD (Intrauterine Device) * Female patients must have a negative urine pregnancy test * Informed Consent Form signed by the subject * Lives and works within a 60 minute drive-time radius of Stanford University * Willing to remain within a 60 minute drive-time radius of Stanford University during all 3 of the 7-day study arms (21 days) * Have someone over 18 years of age who lives with them, Exclusion Criteria: * Current alcohol abuse (intake averaging \> 3 drinks daily in last 30 days), use of marijuana within 1 month of enrollment, or other substance abuse (use within the last 6 months of controlled substances other than marijuana without a prescription) * Subject has a history of diagnosed medical eating disorder * Subject has a history of visual impairment which would not allow subject to participate * Subject has an active skin condition that would affect sensor placement * Subject has adhesive allergies * Subjects requiring an intermediate or long-acting insulin (such as NPH, Neutral Protamine Hagedorn, detemir or glargine) * Subjects requiring other anti-diabetic medications other than insulin (oral or injectable) * Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study * Unwilling or unable to refrain from drinking more than 2 drinks in an hour or more than 4 drinks in a day or use of marijuana during the trial * Subject has active Graves' disease * Subjects with inadequately treated thyroid disease or celiac disease * History of liver disease Renal failure on dialysis * Personal history of cystic fibrosis, pancreatitis, pancreatic tumor, or any other pancreatic disease besides type 1 diabetes * Any known history of coronary artery disease * Abnormal EKG (electrocardiogram) consistent with coronary artery disease or increased risk of malignant arrhythmia * Congestive heart failure (established history of congestive heart failure , lower extremity edema, paroxysmal nocturnal dyspnea, or orthopnea) * History of transient ischemic attack (TIA) or stroke * Seizure disorder, history of any non-hypoglycemic seizure within the last two years, or ongoing treatment with anticonvulsants * History of hypoglycemic seizures (grand-mal) or coma in the last year * History of pheochromocytoma: * episodic or treatment refractory (requiring 4 or more medications to achieve normotension) hypertension * paroxysms of tachycardia, pallor, or headache * personal or family history of MEN 2A (multiple endocrine neoplasia), MEN 2B, neurofibromatosis, or von Hippel-Lindau disease * History of adrenal disease or tumor * Hypertension with systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 despite treatment * Untreated or inadequately treated mental illness * Electrically powered implants (e.g. cochlear implants, neurostimulators) that might be susceptible to RF interference * Unable to completely avoid acetaminophen for duration of study * Established history of allergy or severe reaction to adhesive or tape that must be used in the study * History of eating disorder within the last 2 years, such as anorexia, bulimia, or diabulemia or omission of insulin to manipulate weight * History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment * Lives in or frequents areas with poor Verizon wireless network coverage (which would prevent remote monitoring) * Any factors that, in the opinion of the site principal investigator or overall principal investigator, would interfere with the safe completion of the study